PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease

PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease

BackgroundWe previously demonstrated that subcutaneous administration of PT320, a sustained-release (SR) form of exendin-4, resulted in the long-term maintenance of steady-state exenatide (exendin-4) plasma and target levels in 6-hydroxydopamine (6-OHDA)-pretreated animals. Additionally, pre- or pos...

Full description

Bibliographic Details
Main Authors: Seong-Jin Yu, Shuchun Chen, Yung-Yung Yang, Elliot J. Glotfelty, Jin Jung, Hee Kyung Kim, Ho-Il Choi, Doo-Sup Choi, Barry J. Hoffer, Nigel H. Greig, Yun Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Neuroscience
Subjects:
Parkinson’s disease
levodopa
L-DOPA-induced dyskinesia
glucagon-like peptide-1
exendin-4
PT320
Online Access:https://www.frontiersin.org/article/10.3389/fnins.2020.00785/full

Internet

https://www.frontiersin.org/article/10.3389/fnins.2020.00785/full

Similar Items